Ruxolitinib regulatory update

FDA accepted and granted Priority Review to an NDA from Incyte for ruxolitinib to treat myelofibrosis. The PDUFA date is Dec. 3. An MAA from Novartis, which has ex-U.S. rights to the oral Janus kinas...